Department of Defense Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents.

The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF).

Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.

P&T COMMITTEE MEETING:

May 2024: The following drug classes/subclass will be reviewed: a. Insulins – Subclass: Basal Basaglar Kwikpen U-100 Basaglar Tempo Pen U-100 Insulin Degludec Insulin Degludec Pen (U-100) Insulin Degludec Pen (U-200) Insulin Glargine Insulin Glargine Solostar Insulin Glargine-YFGN Lantus Lantus Solostar Levemir Levemir Flexpen Levemir Flextouch Rezvoglar Kwikpen Semglee Semglee (YFGN) Semglee (YFGN) Pen Semglee Pen Toujeo Max Solostar Toujeo Solostar Tresiba Tresiba Flextouch U-100 Tresiba Flextouch U-200 b. Insulins – Subclass: Rapid-Acting Agents Admelog Admelog Solostar Afrezza Apidra Apidra Solostar Fiasp Fiasp Flextouch Fiasp Penfill Humalog Humalog Junior Kiwkpen Humalog Kwikpen U-100 Humalog Kwikpen U-200 Humalog Tempo Pen U-100 Humulin R Insulin Aspart Insulin Aspart Flexpen Insulin Aspart Penfill Insulin Lispro Insulin Lispro Junior Kwikpen Insulin Lispro Kwikpen U-100 Lyumjev Lyumkev Kwikpen U-100 Lyumjev Kwikpen U-200 Lyumjev Tempo Pen U-100 Novolog Novolog Flexpen Novolog Penfill c. Weight Loss Agents – Subclass: NA Adipex-P Contrave Lomaira Orlistat Qsymia Saxenda Wegovy Xenical Zepbound The RFQ, including UF BPA and UF ADP appendices are attached here in.

The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9201. Pre-proposal teleconference is on January 31, 2024, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.